Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab

Published:2016-04-01 Issue:04 Volume:54 Page:315-322
ISSN:0946-1965
Container-title:Int. Journal of Clinical Pharmacology and Therapeutics
language:en
Short-container-title:CP

Author:

Lambert John,Wyand Michael,Lassen Cheryl,Shneyer Lucy,Thomson Elizabeth,Knight Alastair,Willers Joerg,Kay Jonathan

Publisher

Dustri-Verlgag Dr. Karl Feistle

Subject

Pharmacology (medical),Pharmacology

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infliximab in Inflammatory Bowel Disease: Leveraging Physiologically Based Pharmacokinetic Modeling in the Clinical Context;Biomedicines;2024-09-01

2. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars;Frontiers in Pharmacology;2024-07-24

3. A Randomized, Double‐Blind, Parallel Controlled, Single‐Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects;Clinical Pharmacology in Drug Development;2022-07-02

4. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study;Journal of Crohn's and Colitis;2022-04-07

5. Relapse of severe neurosarcoidosis with switch from originator infliximab to biosimilar;Neurology;2020-05-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP